Cargando…
ODP252 Urosepsis and Sodium-Glucose Co-Transporter-2 Inhibitors: A Systematic Review and Meta-Analysis
OBJECTIVE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are very effective in reducing hemoglobin A1c. They also have benefits in reducing cardiovascular events, heart failure hospitalization, and progression of renal disease in patients with and without T2DM. However, FDA issued a warning for...
Autores principales: | Prasongdee, Klaorat, Toloza, Freddy J, Fernandes, Talmas P, Poloju, Alekya, Lopez-Saldana, Rigoberto, Lock, John P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628163/ http://dx.doi.org/10.1210/jendso/bvac150.700 |
Ejemplares similares
-
THU371 Empagliflozin Associated Pancreatitis: A Case Report
por: Poloju, Alekya, et al.
Publicado: (2023) -
ODP175 COVID-19 Induced Euglycemic Diabetic Ketoacidosis in a Patient taking Sodium-Glucose Cotransporter-2 Inhibitors
por: Alqaisi, Sura, et al.
Publicado: (2022) -
ODP169 Challenges with use of HbA1C for Evaluation of Blood Glucose Control
por: Maletkovic, Jelena
Publicado: (2022) -
ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance
por: Kuwabara, Saki, et al.
Publicado: (2022) -
ODP253 Utilizing EMR Optimization to Streamline Inpatient Blood Glucose Management and Improve Clinician Efficiency
por: Mathews, Tony
Publicado: (2022)